We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

61 hedge funds and large institutions have $566M invested in Kalaris Therapeutics in 2020 Q3 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.4% more ownership

Funds ownership: 0% → 1.4% (+1.4%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Holders
61
Holders Change
+61
Holders Change %
–
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
61
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
$4K
Net Calls
-$4K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$197M
2
RG
Redmile Group
California
+$69.3M
3
AG
Artal Group
Luxembourg
+$69M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$40.3M
5
WP
Woodline Partners
California
+$35.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$173M +$197M +288,106 New
RG
2
Redmile Group
California
$64.2M +$69.3M +101,452 New
AG
3
Artal Group
Luxembourg
$63.9M +$69M +101,016 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$37.3M +$40.3M +58,941 New
WP
5
Woodline Partners
California
$32.8M +$35.4M +51,783 New
BlackRock
6
BlackRock
New York
$32.2M +$34.8M +50,938 New
Alkeon Capital Management
7
Alkeon Capital Management
New York
$30.2M +$32.6M +47,696 New
AllianceBernstein
8
AllianceBernstein
Tennessee
$26.4M +$28.5M +41,684 New
Massachusetts Financial Services
9
Massachusetts Financial Services
Massachusetts
$16.9M +$18.3M +26,786 New
MWNA
10
Marshall Wace North America
New York
$16M +$17.2M +25,256 New
EC
11
EcoR1 Capital
California
$12.3M +$13.3M +19,435 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8.22M +$8.88M +12,997 New
SAM
13
Sectoral Asset Management
Quebec, Canada
$7.64M +$8.25M +12,078 New
State Street
14
State Street
Massachusetts
$6.88M +$7.42M +10,872 New
Northern Trust
15
Northern Trust
Illinois
$5.88M +$6.35M +9,293 New
ACH
16
ArrowMark Colorado Holdings
Colorado
$3.44M +$3.71M +5,435 New
Charles Schwab
17
Charles Schwab
California
$3.01M +$3.25M +4,758 New
SB
18
Samsara BioCapital
California
$2.5M +$2.7M +3,959 New
Carson Wealth (CWM LLC)
19
Carson Wealth (CWM LLC)
Nebraska
$2.22M +$3.34M +4,890 New
N
20
Nuveen
North Carolina
$2.08M +$2.24M +3,282 New
Goldman Sachs
21
Goldman Sachs
New York
$1.72M +$1.85M +2,713 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.45M +$1.56M +2,291 New
Norges Bank
23
Norges Bank
Norway
$1.38M +$1.48M +2,174 New
SCM
24
Suvretta Capital Management
New York
$1.07M +$1.16M +1,696 New
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$1.06M +$1.15M +1,678 New
1
2 3

KLRS Hedge Fund Activity: Q3 2020 in Review

61 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2020, worth a combined $566M.

Buyers outnumbered sellers: 61 funds opened new KLRS positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $197M.

  • 61 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $566M of Kalaris Therapeutics stock for Q3 2020.
  • 61 funds opened new Kalaris Therapeutics positions in Q3 2020 and 0 closed out, a net change of +61 holders.
  • The largest Kalaris Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $197M added.

Based on aggregated 13F filings for Q3 2020.